Guardant Health (NASDAQ:GH) Director Sells $15,102.04 in Stock

Guardant Health, Inc. (NASDAQ:GH) Director Musa Tariq sold 116 shares of the business’s stock in a transaction that occurred on Tuesday, June 16th. The stock was sold at an average price of $130.19, for a total value of $15,102.04. Following the transaction, the director owned 8,796 shares in the company, valued at $1,145,151.24. The trade was a 1.30% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Musa Tariq also recently made the following trade(s):

• On Monday, May 18th, Musa Tariq sold 116 shares of Guardant Health stock. The stock was sold at an average price of $95.96, for a total value of $11,131.36.
• On Thursday, April 16th, Musa Tariq sold 116 shares of Guardant Health stock. The stock was sold at an average price of $84.83, for a total value of $9,840.28.
• On Wednesday, March 18th, Musa Tariq sold 348 shares of Guardant Health stock. The stock was sold at an average price of $88.09, for a total value of $30,655.32.

Guardant Health Price Performance

NASDAQ GH traded down $2.48 on Tuesday, hitting $127.34. 2,672,243 shares of the company’s stock were exchanged, compared to its average volume of 2,126,646. The firm’s 50-day moving average price is $104.23 and its two-hundred day moving average price is $102.22. Guardant Health, Inc. has a fifty-two week low of $40.35 and a fifty-two week high of $135.00. The firm has a market cap of $16.89 billion, a price-to-earnings ratio of -37.56 and a beta of 1.61.

Institutional Investors Weigh In On Guardant Health

Several institutional investors have recently modified their holdings of GH. AQR Capital Management LLC boosted its stake in shares of Guardant Health by 56.5% during the 1st quarter. AQR Capital Management LLC now owns 71,534 shares of the company’s stock worth $3,012,000 after acquiring an additional 25,831 shares in the last quarter. Empowered Funds LLC purchased a new stake in shares of Guardant Health during the 1st quarter worth approximately $274,000. Sei Investments Co. boosted its stake in shares of Guardant Health by 15.8% during the 2nd quarter. Sei Investments Co. now owns 77,308 shares of the company’s stock worth $4,023,000 after acquiring an additional 10,538 shares in the last quarter. The Manufacturers Life Insurance Company boosted its stake in shares of Guardant Health by 9.4% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 632,630 shares of the company’s stock worth $32,922,000 after acquiring an additional 54,284 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Guardant Health by 56.4% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 111,445 shares of the company’s stock valued at $5,800,000 after buying an additional 40,209 shares in the last quarter. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Analysts Set New Price Targets

Several research firms have issued reports on GH. Canaccord Genuity Group boosted their target price on Guardant Health from $125.00 to $135.00 and gave the stock a “buy” rating in a research report on Friday, February 20th. The Goldman Sachs Group began coverage on Guardant Health in a research report on Friday, June 5th. They set a “buy” rating and a $165.00 target price on the stock. Barclays boosted their target price on Guardant Health from $115.00 to $120.00 and gave the stock an “overweight” rating in a research report on Friday, May 8th. Wells Fargo & Company boosted their price target on Guardant Health from $120.00 to $125.00 and gave the stock an “overweight” rating in a research note on Friday, February 20th. Finally, TD Cowen reissued a “buy” rating on shares of Guardant Health in a research note on Thursday, May 21st. One research analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $141.95.

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.